SEATTLE, WA, Jan. 5, 2012 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) today
announced the promotion of Diana Hausman, M.D., to Chief Medical
Officer. Dr. Hausman joined Oncothyreon in August 2009 as Vice
President, Clinical Development.
"Diana has been instrumental in the advancement of our oncology
pipeline, particularly our expansive clinical program for PX-866, a
phosphatidylinositol-3-kinase (PI-3K) inhibitor currently in multiple
Phase 2 clinical trials to evaluate the drug both as a single agent and
in combination with other therapies in a variety of cancer
indications," said Robert L. Kirkman, M.D, President and Chief
Executive Officer. "She has also led planning for the clinical
development of ONT-10, our therapeutic vaccine targeting MUC-1 for
which we recently filed an Investigational New Drug application."
Prior to joining Oncothyreon, Dr. Hausman was employed at Zymogenetics,
Inc., Seattle, Washington, where she held a number of clinical research
positions from 2005 to 2009, including Senior Director of Clinical
Research. Prior to Zymogenetics, Dr. Hausman led a global drug
development team at Berlex Inc. in Seattle from 2002 until 2005.
Oncothyreon is a biotechnology company specializing in the development
of innovative therapeutic products for the treatment of cancer.
Oncothyreon's goal is to develop and commercialize novel synthetic
vaccines and targeted small molecules that have the potential to
improve the lives and outcomes of cancer patients. For more
information, visit www.oncothyreon.com.
SOURCE Oncothyreon Inc.
For further information:
Investor and Media Relations Contact: